EyeConic: Qualification for Cone-Optogenetics

NCT ID: NCT05294978

Last Updated: 2025-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Dystrophies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

-Availability of macular optical coherence tomography (OCT)

Optical coherence tomography (OCT)

Intervention Type DIAGNOSTIC_TEST

Data of macular optical coherence tomography (OCT)

Controls

-Availability of macular optical coherence tomography (OCT)

Optical coherence tomography (OCT)

Intervention Type DIAGNOSTIC_TEST

Data of macular optical coherence tomography (OCT)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optical coherence tomography (OCT)

Data of macular optical coherence tomography (OCT)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of generalized IRD
* Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye
* Availability of macular optical coherence tomography (OCT)


* Normal ophthalmic findings
* Availability of macular optical coherence tomography (OCT)

Exclusion Criteria

* Other eye diseases with a significant effect on vision or retinal structure
* Extraocular disease affecting retinal structure such as neurodegenerative diseases
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institute of Molecular and Clinical Ophthalmology Basel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicolas Feltgen, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Basel/Institute of Molecular and Clinical Ophthalmology Basel, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California San Francisco, Department of Ophthalmology

San Francisco, California, United States

Site Status RECRUITING

Bascom Palmer Eye Institute

Miami, Florida, United States

Site Status RECRUITING

University of Pittsburgh, Department of Ophthalmology

Pittsburgh, Pennsylvania, United States

Site Status RECRUITING

Beijing Institute of Ophthalmology

Beijing, , China

Site Status RECRUITING

Universitätsklinikum Tübingen Augenklinik

Tübingen, , Germany

Site Status RECRUITING

Semmelweis University, Department of Ophthalmology

Budapest, , Hungary

Site Status RECRUITING

Oculista Ospedale Parma

Parma, , Italy

Site Status RECRUITING

University Hospital Basel, Eye Clinic

Basel, , Switzerland

Site Status RECRUITING

Moorfields Eye Hospital

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States China Germany Hungary Italy Switzerland United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lucas Janeschitz-Kriegl, MD

Role: CONTACT

+41787494373

Tiana Koottungal

Role: CONTACT

+41788486737

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stefano Gandolfi, MD

Role: primary

Nicolas Feltgen, MD

Role: primary

+41612659292

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IOB_EyeConic_2021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Promising ROd-cone DYstrophy Gene therapY
NCT05748873 RECRUITING PHASE1/PHASE2
BS01 in Patients With Retinitis Pigmentosa
NCT04278131 RECRUITING PHASE1/PHASE2
Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736 COMPLETED PHASE2/PHASE3